Table 2.
Summary of comparisons of relevant measurements among the sepsis patients receiving Shenmai injection plus regular treatment versus regular treatment alone.
| Outcome | No. of studies | No. of participants | Heterogeneity | Statistical method | Effect estimates | ||
|---|---|---|---|---|---|---|---|
| I 2 | p | Effect size (95% CI) | P value | ||||
| Coagulation function | |||||||
| PT | 6 | 456 | 84% | <0.00001 | SMD, Fixed | −1.35 (−1.55, −1.14) | <0.00001 |
| TT | 3 | 256 | 25% | 0.27 | SMD, Fixed | −1.76 (−2.05, −1.47) | <0.00001 |
| APTT | 6 | 419 | 88% | <0.00001 | SMD, Random | −0.85 (−1.45, −0.25) | 0.005 |
| FIB | 4 | 272 | 69% | 0.02 | SMD, Random | 1.24 (0.76, 1.73) | <0.00001 |
| PLT | 6 | 432 | 90% | <0.00001 | SMD, Random | 1.05 (0.37, 1.73) | 0.002 |
| D-D | 5 | 356 | 82% | 0.0002 | SMD, Random | −0.97 (−1.51, −0.43) | 0.0005 |
|
| |||||||
| Immune function | |||||||
| CD3 | 2 | 158 | 0% | 0.41 | SMD, Fixed | 0.58 (0.27, 0.90) | 0.0003 |
| CD4 | 2 | 152 | 0% | 0.48 | SMD, Fixed | 0.97 (0.64, 1.31) | <0.00001 |
| CD8 | 2 | 152 | 89% | 0.003 | SMD, Random | −0.51 (−1.57, 0.55) | 0.35 |
| CD4/CD8 | 2 | 158 | 25% | 0.25 | SMD, Fixed | 0.74 (0.42, 1.07) | <0.00001 |
| NK | 3 | 264 | 94% | <0.00001 | SMD, Random | 0.24 (−0.77, 1.25) | 0.65 |
|
| |||||||
| Inflammation factor | |||||||
| IL-1 | 4 | 302 | 98% | <0.00001 | SMD, Random | −0.15 (−2.1, 1.8) | 0.88 |
| IL-8 | 3 | 252 | 95% | <0.00001 | SMD, Random | −1.66 (−2.99, −0.33) | 0.01 |
|
| |||||||
| Organ function | |||||||
| ALT | 3 | 252 | 98% | <0.00001 | SMD, Random | −4.85 (−8.13, −1.57) | 0.004 |
| AST | 3 | 252 | 0% | 0.97 | SMD, Fixed | −6.13 (-6.73, −5.53) | <0.00001 |
| BUN | 3 | 252 | 87% | 0.0004 | SMD, Random | −1.63 (−1.92, −1.34) | <0.00001 |
| Cr | 5 | 375 | 98% | <0.00001 | SMD, Random | −2.71 (−4.79, −0.64) | 0.01 |
| LDH | 2 | 172 | 36% | 0.21 | SMD, Fixed | −2.00 (−2.45,−1.5) | <0.00001 |
| CK | 4 | 358 | 96% | <0.00001 | SMD, Random | −1.57 (−2.82, −0.33) | 0.01 |
| CK-MB | 7 | 513 | 84% | <0.00001 | SMD, Random | −1.07 (−1.55, −0.59) | <0.0001 |
| BNP | 4 | 261 | 42% | 0.16 | SMD, Fixed | −0.45 (−0.69, −0.20) | 0.0004 |
| TnI | 3 | 198 | 29% | 0.24 | SMD, Random | −0.67 (−1.02, −0.31) | 0.0003 |
|
| |||||||
| Others | |||||||
| WBC | 3 | 180 | 0% | 0.76 | SMD, Fixed | −0.11 (−0.41, 0.18) | 0.44 |
| Hb | 3 | 163 | 0% | 0.78 | SMD, Fixed | 14.59 (9.7, 19.48) | <0.00001 |
Note. No., number; EG, experimental group; CRP, C-reaction protein; IL-6, interleukin-6; NK, natural killer; ALT, alanine transaminase; AST, aspartate transaminase; BUN, blood urea nitrogen; Cr, creatinine; LDH, lactate dehydrogenase; CK, creatine kinase; CK-MB, creatine kinase isoenzyme-MB; APTT, activated partial thromboplastin time; PT, prothrombin time; TT, thrombin time; FIB, fibrinogen; PLT, platelet; D-D, D-dimer; IL-1, interleukin-1; TNF-α, tumor necrosis factor-α; IL-8, interleukin-8; WBC, white blood cell; Hb, hemoglobin; BNP, B-brain natriuretic peptide; TnI, troponin I.